Overview

Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia and Hyperlipidemia

Status:
Not yet recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SHR-1209 subcutaneous administration in patients with hypercholesterolemia and hyperlipidemia after lipid-lowering therapy
Phase:
Phase 3
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.